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Abstract 
 
The taste receptor type 1 (TAS1R) family of heterotrimeric G protein-coupled receptors participates in monitoring 
energy and nutrient status. TAS1R member 3 (TAS1R3) is a bi-functional protein that recognizes amino acids such 
as L-glycine and L-glutamate or sweet molecules such as sucrose and fructose when dimerized with TAS1R 
member 1 (TAS1R1) or TAS1R member 2 (TAS1R2), respectively. It was recently reported that deletion of 
TAS1R3 expression in Tas1R3 mutant mice leads to increased cortical bone mass but the underlying cellular 
mechanism leading to this phenotype remains unclear. Here, we independently corroborate the increased thickness 
of cortical bone in femurs of 20-week-old male Tas1R3 mutant mice and confirm that Tas1R3 is expressed in the 
bone environment. Tas1R3 is expressed in undifferentiated bone marrow stromal cells (BMSCs) in vitro and its 
expression is maintained during BMP2-induced osteogenic differentiation. However, levels of the bone formation 
marker Procollagen Type I N-terminal Propeptide (PINP) are unchanged in the serum of 20-week-old Tas1R3 
mutant mice as compared to controls. In contrast, levels of the bone resorption marker Collagen Type I C-
telopeptide are reduced greater than 60% in Tas1R3 mutant mice. Consistent with this, Tas1R3 and its putative 
signaling partner Tas1R2 are expressed in primary osteoclasts and their expression levels positively correlate with 
differentiation status. Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to 
uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining 
the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling. 
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Background 
 
Osteoporosis is a disease of low bone mineral density that is both a significant health problem and a considerable 
socioeconomic burden, accounting for 1.5 million fractures annually in the United States [18,2]. Osteoporosis is 
characterized by an imbalance in bone remodeling in which bone resorption by osteoclasts outpaces bone formation 
by osteoblasts. Current treatments for osteoporosis have significant limitations [18,3,1,7], and a better understanding 
of the endogenous mechanisms regulating bone remodeling is necessary for developing novel treatment strategies. 
Recent evidence implicates the taste receptor type 1 (TAS1R) family as a novel mechanism regulating postnatal 
bone homeostasis [16].  
 
The TAS1R family members TAS1R1, TAS1R2, and TAS1R3 act as nutrient sensors to monitor energy and nutrient 
status and are expressed in numerous oral and extra-oral tissues including the gastrointestinal tract, brain, bladder, 
pancreas, male reproductive organs, immune system, adipose tissue, and bone [11]. TAS1R3 is a bi-functional, class 
C heterotrimeric G protein-coupled receptor that recognizes amino acids such as L-glycine and L-glutamate when 
dimerized with TAS1R1 or sweet molecules such as sucrose and fructose when dimerized with TAS1R2. Regardless 
of the ligand, these two responses share a common signaling pathway involving α-gustducin-mediated activation of 
Phospholipase C-β2 (PLCβ2) [11].  
 
Recently, Simon et al. reported that deletion of the gene encoding TAS1R3 in Tas1R3 mutant mice leads to 
increased cortical bone mass [16]; however, the underlying cellular mechanism leading to this phenotype was not 
examined. Here, we corroborate the finding of high bone mass in Tas1R3 mutant mice and report that levels of the 
bone resorption marker Collagen Type I C-telopeptide are reduced greater than 60% in these mice while bone 
formation markers are unchanged. Consistent with this, Tas1R3 and its putative partner Tas1R2 are expressed in 
primary osteoclasts and their expression levels positively correlate with differentiation status. Collectively, these 
findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced 
osteoclast function and provide rationale for future experiments examining the cell type-dependent role for TAS1R 
family members in nutrient sensing in postnatal bone remodeling.  
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Materials and Methods 
 
Animals 
 
Tas1R3 mutant mice were described previously [19]. Wild type C57Bl/6 mice were purchased from Charles River 
Labs. Animals were given humane care with compliance to institutional guidelines and were allowed ad libitum 
access to standard chow and tap water under temperature controlled conditions. Euthanasia was accomplished via 
exposure to CO2 followed by cervical dislocation. 
 
Micro computed tomography (µCT) and histomorphometric analyses 
 
For µCT analyses, bones were collected immediately after sacrifice and fixed in 10% neutral buffered formalin 
(Millipore, Billerica, Massachusetts, USA). Bones were exchanged to 70% ethanol, stored at 4°C, and analyzed at 
the Harvard School of Dental Medicine µCT Core Facility on a SCANCO µCT 35 scanner. Bone volume and 
mineral density were determined using the following settings: FOV/Diameter: 7168 µm; voxel size: 7.0 µm; slice 
increment: 7.0 µm; projections: 500; sample time: 600 ms; µ-scaling: 4096; energy: 55000 V; intensity: 145 µA. 
The reader is directed to an excellent guide to µCT in rodents [4]. Femora were subsequently embedded in methyl 
methacrylate without decalcification, stained using hematoxylin and eosin, von Kossa/McNeal, or for TRAP activity 
counterstained with hematoxylin as previously described [15]; quantification for standard histomorphometric 
parameters (n=3 per genotype) by a blinded scorer using morphometric software (OsteoMetrics, Atlanta, Georgia, 
USA). The reader is directed to an excellent guide to bone histomorphometry [5]. 
 
Cell culture 
 
MC3T3-E1 and MLO-Y4 cells were obtained from ATCC. Bone marrow stromal cells (BMSCs) were isolated from 
the long bones of male C57Bl/6 mice (Charles River Labs, Wilmington, Massachusetts, USA) between ten and 
thirteen weeks of age as previously described [9]. Cells were maintained in DMEM (MC3T3-E1 and MLO-Y4 cells) 
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or α-MEM (BMSCs) supplemented with 10% FBS (Thermo-Fisher Scientific, Waltham, Massachusetts, USA). 
BMSC differentiation was accomplished by treatment with 100 ng/ml BMP2 (R&D Systems, Minneapolis, 
Minnesota, USA) for seven days; RNA was isolated on day 0 and day seven for subsequent RT-PCR analyses. 
 
Primary bone marrow macrophages (BMMs) were flushed from femurs and tibiae of C57Bl/6 mice. Red blood cells 
were lysed with RBC lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH7.4). BMMs were spun 
down, resuspended in minimal essential media α (Thermo-Fisher Scientific) supplemented with 1% CMG 14-12 
cultured supernatant containing M-CSF, and plated on 100 mm tissue culture plates overnight.   The   following   
day,   the   non-adherent   population   of   cells was   counted   and   plated   for experiments.  Cells  were  
maintained  in  medium  containing  M-CSF  for  two  more  days,  at  which  time media was replaced with medium 
containing 1% CMG 14-12 culture supernatant and 30 ng/mL RANKL (R&D Systems) to initiate osteoclast 
differentiation for up to three days before harvesting. 
 
Gene expression analyses 
 
For gene expression studies, total RNA was isolated from isolated cells or marrow-free humerii as previously 
described [13]. Reverse transcription was performed using the SuperScript III First-Strand Synthesis SuperMix 
(Thermo-Fisher Scientific); cDNA from primary murine osteoclasts was generated as described previously [15]. 
PCR was carried out with GoTaq (Promega, Madison, Wisconsin, USA) or OneTaq (New England Biolabs, 
Ipswich, Massaschusetts, USA) and the following primer pairs: Tas1R1, 5’-CTGCCAAAGGACAGAATCCTC-3’ 
and 5’-GAACCGCATGGCTTGGAAG-3’; Tas1R2, 5’- AGCGTGTGGTCTACAGTGTG-3’ and 5’-
TCTCCCTGAGTAGCTGCCAT-3’; Tas1R3, 5’-TGGGGGCCTCTTTGTGTCT-3’ and 5’-
TGGGTTGTGTTCTCTGGTTGA-3’; Ctsk, 5’- AGCGAACAGATTCTCAACAGC-3’ and 5’-
AGACAGAGCAAAGCTCACCAT-3’; Osterix/Sp,, 5’-AGAGATCTGAGCTGGGTAGAGG-3’ and 5’-
AAGAGAGCCTGGCAAGAGG-3’; Rankl/Tnfsf11, 5’-AGCCATTTGCACACCTCAC-3’ and 5’-
CGTGGTACCAAGAGGACAGAGT-3’; Trap/Acp5, 5’-CGTCTCTGCACAGATTGCAT-3’ and 5’-
AAGCGCAAACGGTAGTAAGG-3’; Hprt, 5’-CCTGCTGGATTACATTAAAGCACTG-3’ and 5’-
6 
 
GTCAAGGGCATATCCAACAACAAAC-3’. Negative controls for PCR targets were accomplished using reactions 
lacking template DNA.  
 
For quantitative real-time PCR experiments, RNA was harvested from BMSCs or osteoclasts using TRIzol Reagent 
(Thermo-Fisher Scientific) or RNEasy Kit (QIAGEN, Hilden, Germany).  cDNA  was  prepared  using  the  iScript 
cDNA  Synthesis  Kit  (Biorad, Hercules, California, USA). Reactions were run using LightCycler 480 SYBR Green 
I Master (Roche, Basel, Switzerland) on the Roche LightCycler 480 using the primer pairs listed above. 
 
Serum immunoassays 
 
Serum samples were obtained as previously described [17] and levels of PINP, CTx, and TRAP were measured 
using the Mouse PINP ELISA Kit, Mouse CTX-1 ELISA Kit, and Mouse TRAP ELISA Kit by NeoScientific 
(Cambridge, Massachusetts, USA), respectively, according to the manufacturer’s instructions.  
 
Statistical considerations 
 
Data were plotted in GraphPad Prism 6 and statistical tests completed as detailed in the figure or table legends; 
p<0.05 was considered significant. 
 
Results 
 
Increased cortical bone in Tas1R3 mutant mice  
We first sought to corroborate the report of increased cortical bone mass in the femora of Tas1R3 mutant mice. 
Similar to the report by Simon et al [15], μCT analyses performed on a small cohort of twenty-week-old male mice 
revealed a modest increase (+13%) in average thickness of the cortical bone at the femoral mid-diaphysis of Tas1R3 
mutant mice as compared to wild type littermates (Figure 1A-B). And, consistent with our previous results [9], RT- 
PCR analysis on RNA from marrow-free humeral diaphyses of nine-week-old wild type mice confirmed that 
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Tas1R3 is expressed in the postnatal bone micro-environment along with its putative signaling partners Tas1R1 and 
Tas1R2 (Figure 1C).  
  
TAS1R3 in bone formation 
 We next sought to determine if osteoblast lineage cells express TAS1R3. These experiments revealed that Tas1R3 
transcript is present in undifferentiated primary murine bone marrow stromal cells (BMSCs) (Figure 2A) and its 
expression level is maintained during BMP2-induced differentiation of these cells (Figure 2B); increased expression 
of the osteoblast lineage marker Osterix/Sp7 (Figure 2C) serves as a positive control for differentiation in this assay. 
Consistent with this result, Tas1R3 transcript is present in the osteoblastic cell line MC3T3-E1 and the osteocyte- 
like cell line MLO-Y4 (Figure 2D); no attempt was made to quantitatively compare expression levels of Tas1R3 
between these cell lines or against primary BMSCs. 
 
These findings raised the possibility that loss of TAS1R3 function in the osteoprogenitor lineage might underlie high 
bone mass in Tas1R3 mutant mice. To test this idea, we examined osteoblast parameters by static histomorphometry 
and osteoblast function by quantifying serum levels of the bone formation marker Procollagen Type I N-terminal 
Propeptide (PINP). No differences were observed between control and Tas1R3 mutant mice in these analyses (Table 
1 and Figure 2E) suggesting that, although cells of the bone-forming lineage express TAS1R3, its absence does not 
lead to altered osteoblast differentiation or activity. 
 
TAS1R3 in bone resorption  
We next examined a possible role for TAS1R3 in bone resorption and found that serum levels of the bone resorption 
marker Collagen Type I C-telopeptide (CTx) are reduced by greater than 60% in Tas1R3 mutant mice (Figure 3A). 
Consistent with this idea, Tas1R3 is expressed in primary murine osteoclasts in vitro along with its putative 
signaling partner Tas1R2 (Figure 3B); Tas1R1 expression was not observed in these cells (data not shown). 
Additionally, increased expression of Tas1R3 and Tas1R2 correlate with the robust increase in expression of the 
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mature osteoclast marker Cathepsin K (Ctsk) observed during the differentiation period (Figure 3C-E). These data 
raised the possibility that defective osteoclast differentiation may underlie the reduction in bone resorption observed 
in Tas1R3 mutant mice. However, static histomorphometric analyses indicate that osteoclast number is unchanged in 
the absence of TAS1R3 (Table 1), which is supported by the fact that skeletal expression levels of Rankl/Tnfsf11 
(Figure 3F) and Trap/Acp5 (Figure 3G) and serum levels of TRAP (Figure 3H) are comparable between control and 
Tas1R3 mutant mice. Collectively, our findings suggest that global absence of TAS1R3 function leads to uncoupled 
bone remodeling due to reduced osteoclast activity. 
 
Discussion 
 
Our study corroborates the finding of elevated cortical bone mass in Tas1R3 mutant mice recently reported by 
Simon et al. [16] and addresses the open question regarding the cellular mechanism(s) underlying high bone mass in 
mice. Although Tas1R3 expression has been previously observed in the skeleton [10], we are the first to detail the 
specific skeletal cell types that express TAS1R family members in vitro. In particular, Tas1R3 and Tas1R2 are 
expressed endogenously in murine osteoclast precursors, and their expression levels parallel the robust increase in 
the osteoclast marker Ctsk during osteoclast differentiation. In contrast, Tas1R1 expression is undetectable in these 
assays, suggesting TAS1R3 functions in conjunction with TAS1R2 in osteoclasts. This idea is consistent with the 
fact that, similar to Tas1R3 mutant mice, global loss of Tas1R2 also leads to high bone mass through an 
undetermined mechanism [16].  
 
The specific role that TAS1R2 and TAS1R3 play in osteoclast cells remains unknown. However, a requirement for 
TAS1R3 function in bone resorption in vivo is confirmed by the fact that Tas1R3 mutant mice display a profound 
reduction in serum levels of the bone resorption marker CTx in comparison to wild type mice. In contrast, TAS1R 
family members are expressed in the osteoblast lineage in vitro, yet serum levels of the bone formation marker PINP 
are unchanged in Tas1R3 mutant mice. While we are unable to comment on the specific molecule(s) mediating 
activation of TAS1R2 and TAS1R3 in the osteoclast lineage in vivo, glucose is one compelling possibility among 
the host of putative ligands [14]. For example, reducing glucose availability impairs osteoclast activity in vitro [8], 
and glycolytic inhibitors reduce bone resorption in vivo [12,6]. This presents the hypothesis that reduced glucose 
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sensing by osteoclasts in Tas1R3 mutant mice leads to defective bone resorption. Additionally, prior work indicates 
that loss of TAS1R3 function is associated with decreased mammalian target of rapamycin complex 1 (mTORC1) 
activity and increased autophagy [17]. We must also acknowledge that the global nature of the Tas1R3 mutation, 
coupled with the expression of this receptor in numerous extra-skeletal sites [11], leaves open the possibility that 
impairment of bone resorption in Tas1R3 mutant mice is secondary to losing TAS1R3 function in another 
physiological context. Future studies involving cell type-dependent knockout of Tas1R3 are required to differentiate 
between these possibilities, but these studies are not yet possible due to the lack of a conditional Tas1R3 allele. 
 
In conclusion, our findings provide novel insight into the role of TAS1R family members in skeletal biology and 
postnatal bone remodeling. These results and the stated limitations provide rationale for future experiments 
examining the cell type-dependent role for TAS1R family members in nutrient sensing by osteoclasts and/or 
osteoblasts in the postnatal skeleton.  
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Table 1. Histomorphometric analysis of femora obtained from twenty-week-old wild type and Tas1R3 knock-out 
(KO) mice. Data are expressed as mean±SEM and p values generated by unpaired t tests. Ob.N: osteoblast number; 
B.Pm: bone perimeter; Ob.S: osteoblast surface; BS: bone surface; Oc.N: osteoclast number. 
 
 Parameter Wild Type Tas1R3 KO p value 
Trabecular 
Osteoblast Number 
(Ob.N/B.Pm) 20.78±3.288 16.07±2.767 0.3344 
Osteoblast Surface 
(Ob.S/BS) 14.8±3.523 12.88±2.921 0.6956 
Osteoclast Number 
(Oc.N/B.Pm) 7.621±0.9471 8.358±1.009 0.6226 
Osteoclast Surface 
(Oc.S/BS) 16.03±2.427 15.88±2.127 0.9639 
Cortical 
Osteoclast Number 
(Oc.N/B.Pm) 5.230±1.540 6.219±1.863 0.7035 
Osteoclast Surface 
(Oc.S/BS) 0.09106±0.02639 0.1183±0.04087 0.6314 
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Figure Legends 
 
Fig. 1: Evaluation of bone mass in Tas1R3 mutant mice. A-B: A, Quantification of average thickness of the cortical 
bone (cortical thickness, C.Th) at the femoral mid-diaphysis of twenty-week-old male Tas1R3 knock-out (KO) as 
compared to wild types; data are expressed as mean±SEM, n=3 for each genotype and * indicates p<0.05 by 
unpaired t test. B, Images of mid-diaphyseal bone for wild type and Tas1R3 KO most representative of the genotype 
mean in A; scale bar is 200 μm. C: RT-PCR for TAS1R family members in nine-week-old marrow-free humeral 
diaphysis from wild type mouse; Hprt serves as loading control. Data are representative of five marrow-free 
humerii. 
 
Fig. 2: TAS1R3 in bone formation. A: RT-PCR for Tas1R3 in undifferentiated wild type primary murine bone 
marrow stromal cells (BMSC); Hprt serves as loading control. B-C: Quantification of Tas1R3 (B) and Osterix (C) 
expression during BMP2-induced differentiation of BMSCs (data are expressed as mean±SEM from four separate 
isolation/differentiation experiments and * indicates p<0.05 by ratio paired t-test). D: RT-PCR for Tas1R3 in 
osteoblastic MC3T3-E1 cells and osteocyte-like MLO-Y4 cells; Hprt serves as loading control. E: Quantification of 
Procollagen Type I N-terminal Propeptide (PINP) levels in serum from twenty-week-old male wild type and Tas1R3 
knock-out (KO) mice; data are expressed as mean±SEM. n≥5 for each group. p=0.7 by unpaired t test. 
 
Fig. 3: TAS1R3 in bone resorption. A: Quantification of Collagen Type I C-telopeptide (CTx) levels in serum from 
twenty-week-old male wild type and Tas1R3 knock-out (KO) mice; data are expressed as mean±SEM. n=3 for each 
group. * indicates p<0.04 by unpaired t test.B: RT-PCR for TAS1R family members in differentiated primary 
murine osteoclasts (OCLs). Hprt serves as loading control. Data are representative of four independent differentiated 
OCL samples. C-E: Quantitative RT-PCR for Tas1R3 (C) and Tas1R2 (D) expression from non-adherent murine 
bone marrow cells undergoing osteoclast differentiation in vitro. Cathepsin K (Ctsk) serves as positive control for 
osteoclast differentiation (E). Data are expressed as mean±SEM fold change relative to time course day zero from 
five independent experiments. * indicates p<0.02 by ratio paired t test. F-G: Quantitative RT-PCR for Rankl/Tnfsf11 
(F) and Trap/Acp5 (G) using RNA obtained from twenty-week-old humerii; data are expressed as mean±SEM. n=5 
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for each group. H: Quantification of TRAP levels in serum from twenty-week-old male mice; data are expressed as 
mean±SEM. n=8 for each group. 
